

Highlights of This Issue 979

REVIEWS

- 981** The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target
Melanie A. Blevins, Mingxia Huang, and Rui Zhao

- 991** FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia and Maria R. Baer

- 1002** The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma
Antonio Ahn, Aniruddha Chatterjee, and Michael R. Eccles

SMALL MOLECULE THERAPEUTICS

- 1010** Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor



Timothy P.S. Perera, Eleonora Jovcheva, Laurence Mevellec, Jorge Vialard, Desiree De Lange, Tinne Verhulst, Caroline Paulussen, Kelly Van De Ven, Peter King, Eddy Freyne, David C. Rees, Matthew Squires, Gordon Saxty, Martin Page, Christopher W. Murray, Ron Gilissen, George Ward, Neil T. Thompson, David R. Newell, Na Cheng, Liang Xie, Jennifer Yang, Suso J. Platero, Jayaprakash D. Karkera, Christopher Moy, Patrick Angibaud, Sylvie Laquerre, and Matthew V. Lorenzi

- 1021** The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Hui Zhang, Atish Patel, Yi-Jun Wang, Yun-Kai Zhang, Rishil J. Kathawala, Long-Hui Qiu, Bhargav A. Patel, Li-Hua Huang, Suneet Shukla, Dong-Hua Yang, Suresh V. Ambudkar, Li-Wu Fu, and Zhe-Sheng Chen

- 1031** Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Nicolas Floc'h, Susan Ashton, Paula Taylor, Dawn Trueman, Emily Harris, Rajesh Odedra, Kim Maratea, Nicola Derbyshire, Jacqueline Caddy, Vivien N. Jacobs, Maureen Hattersley, Shenghua Wen, Nicola J. Curtis, James E. Pilling, Elizabeth J. Pease, and Simon T. Barry

- 1041** Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor

Casey G. Langdon, James T. Platt, Robert E. Means, Pinar Iyidogan, Ramanaiah Mamillapalli, Michael Klein, Matthew A. Held, Jong Woo Lee, Ja Seok Koo, Christos Hatzis, Howard S. Hochster, and David F. Stern

- 1054** Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Stuart W. Ember, Que T. Lambert, Norbert Berndt, Steven Gunawan, Muhammad Ayaz, Marilena Tauro, Jin-Yi Zhu, Paula J. Cranfill, Patricia Greninger, Conor C. Lynch, Cyril H. Benes, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, and Ernst Schönbrunn

- 1068** The TLR3 Agonist Inhibit Drug Efflux and Sequentially Consolidates Low-Dose Cisplatin-Based Chemoimmunotherapy while Reducing Side Effects
Liang Ding, Jing Ren, Dongya Zhang, Yi Li, Xiaofeng Huang, Jianjian Ji, Qingang Hu, Hui Wang, Yanhong Ni, and Yayi Hou

- 1080** G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly
Xiangmin Lv, Chunbo He, Cong Huang, Guohua Hua, Zhengfeng Wang, Steven W. Remmenga, Kerry J. Rodabough, Adam R. Karpf, Jixin Dong, John S. Davis, and Cheng Wang

- 1092** Fluorouracil Enhances Photodynamic Therapy of Squamous Cell Carcinoma via a p53-Independent Mechanism that Increases Protoporphyrin IX levels and Tumor Cell Death
Sanjay Anand, Kishore R. Rollakanti, Nikoleta Brankov, Douglas E. Brash, Tayyaba Hasan, and Edward V. Maytin

LARGE MOLECULE THERAPEUTICS

- 1102** A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio
Ming-Hsien Chien, Wei-Min Chang, Wei-Jiunn Lee, Yu-Chan Chang, Tsung-Ching Lai, Derek V. Chan, Rahul Sharma, Yuan-Feng Lin, and Michael Hsiao

Table of Contents

1114 Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)

Michael J. Wagner, Rahul Mitra, Mark J. McArthur, Wallace Baze, Kirstin Barnhart, Sherry Y. Wu, Cristian Rodriguez-Aguayo, Xinna Zhang, Robert L. Coleman, Gabriel Lopez-Berestein, and Anil K. Sood

1124 Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer

Akihisa Kato, Hiromi Kataoka, Shigenobu Yano, Kazuki Hayashi, Noriyuki Hayashi, Mamoru Tanaka, Itaru Naitoh, Teshin Ban, Katsuyuki Miyabe, Hiromu Kondo, Michihiro Yoshida, Yasuaki Fujita, Yasuki Hori, Makoto Natsume, Takashi Murakami, Atsushi Narumi, Akihiro Nomoto, Aya Naiki-Ito, Satoru Takahashi, and Takashi Joh

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

1133 Focal Adhesion Kinase as a Potential Target in AML and MDS

Bing Z. Carter, Po Yee Mak, Xiangmeng Wang, Hui Yang, Guillermo Garcia-Manero, Duncan H. Mak, Hong Mu, Vivian R. Ruvolo, Yihua Qiu, Kevin Coombes, Nianxiang Zhang, Brittany Ragon, David T. Weaver, Jonathan A. Pachter, Steven Kornblau, and Michael Andreeff

1145 Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition

Mei Hua Jin, Ah-Rong Nam, Ji Eun Park, Ju-Hee Bang, Yung-Jue Bang, and Do-Youn Oh

1155 Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma

Yoshiteru Ohata, Shu Shimada, Yoshimitsu Akiyama, Kaoru Mogushi, Keisuke Nakao, Satoshi Matsumura, Arihiro Aihara, Yusuke Mitsunori, Daisuke Ban, Takanori Ochiai, Atsushi Kudo, Shigeki Arii, Minoru Tanabe, and Shinji Tanaka

1166 Disruption of TCF/ β -Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells

Esther Martinez-Font, Irene Felipe-Abrio, Silvia Calabuig-Fariñas, Rafael Ramos, Josefa Terrasa, Oliver Vögler, Regina Alemany, Javier Martín-Broto, and Antònia Obrador-Hevia

1177 Biological Role and Therapeutic Targeting of TGF- β_3 in Glioblastoma

Katharina Seystahl, Alexandros Papachristodoulou, Isabel Burghardt, Hannah Schneider, Kathy Hasenbach, Michel Janicot, Patrick Roth, and Michael Weller

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

1187 PMP22 Regulates Self-Renewal and Chemoresistance of Gastric Cancer Cells

Wangyu Cai, Gang Chen, Qicong Luo, Jun Liu, Xiaofeng Guo, Tian Zhang, Fei Ma, Liang Yuan, Boan Li, and Jianchun Cai

CORRECTION

1199 Correction: Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover illustrates the binding mode of ibrutinib with homology modeled ABCB1 predicted by XP-Glide. The docked conformation of ibrutinib as ball and stick model is shown within the large hydrophobic cavity of ABCB1. Important amino acids are depicted as sticks with the carbon atoms colored in green, hydrogen in white, nitrogen in blue, oxygen in red and sulfur in yellow, whereas ibrutinib is shown with the same color scheme as above except carbon atoms are represented in orange. Dotted black line indicates hydrogen-bonding interactions. Molecular surface of homology modeled ABCB1 was colored in yellow which indicated the hydrophobic nature of ibrutinib-binding pocket.



Molecular Cancer Therapeutics

16 (6)

Mol Cancer Ther 2017;16:979-1199.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/16/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/16/6>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.